Onychomycosis Alternative

Article

San Francisco - The key to effectively treating toenail and fingernail onychomycosis may lay in the delivery system rather than in the drug itself, according to preliminary results of an open-label feasibility study of a 4 percent clotrimazole lacquer formulated with the drug delivery technology CPE-215 (15 percent).

Related Videos
Related Content

Pointers With Portela: Careers With an Increased Skin Cancer Risk

October 4th 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

Utilizing Naturally Occurring Compounds for Treatment of Coexisting Vitiligo and Psychiatric Conditions

October 4th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Real-World Insights: Systemic Therapies in Moderate to Severe Atopic Dermatitis Patients

October 3rd 2023

Larry Eichenfield, MD, Addresses Pediatric AD, Upcoming Therapies, and Misinformation From Social Media

October 3rd 2023

Pointers With Portela: Careers With an Increased Skin Cancer Risk

October 4th 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

Utilizing Naturally Occurring Compounds for Treatment of Coexisting Vitiligo and Psychiatric Conditions

October 4th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Real-World Insights: Systemic Therapies in Moderate to Severe Atopic Dermatitis Patients

October 3rd 2023

Larry Eichenfield, MD, Addresses Pediatric AD, Upcoming Therapies, and Misinformation From Social Media

October 3rd 2023

Pointers With Portela: Careers With an Increased Skin Cancer Risk

October 4th 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

Utilizing Naturally Occurring Compounds for Treatment of Coexisting Vitiligo and Psychiatric Conditions

October 4th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Real-World Insights: Systemic Therapies in Moderate to Severe Atopic Dermatitis Patients

October 3rd 2023

Larry Eichenfield, MD, Addresses Pediatric AD, Upcoming Therapies, and Misinformation From Social Media

October 3rd 2023
© 2023 MJH Life Sciences

All rights reserved.